When and How to Conduct Health Technology Assessments for Biosimilars?
ISPOR鈥擳he Professional Society for Health Economics and Outcomes ResearchISPOR announced the publication of a report from the ISPOR Biosimilars Special Interest Group highlighting the need for clearer guidance on when and how to conduct health technology assessments (HTAs) for biosimilars.